Produced in partnership with Two Photon
Neurons and cancer cells are a dangerous duo
New research finds that neurons migrate from the brain to infiltrate cancer cells, and that targeting this process is a promising new method of attack on cancer.
Scientists have thoroughly studied the connections between the central nervous system and other systems, because our brain controls pretty much everything in our body: our movements, our emotions, and even our gut. Now, researchers are starting to realize the brain might also control something much more sinister - cancer.
Malignant tumors are groups of abnormal cells that can divide quickly, spread, and ultimately develop into cancer. In 2001, cancer biologists discovered the presence of nerve fibers—the projections that come from neurons—in tumors. Although neurons are typically regarded as harmless or perhaps even beneficial, this turned out not to be true in tumors. It appears that tumors can co-opt the signals neurons produce in order to grow, such as growth factors and neurotransmitters—hinting that neurons and cancer cells together might be a dangerous duo.
While the relationship is still being explored, studies across many different types of cancer suggest the presence of neuronal connections in tumors may be detrimental. For example, a high number of nerve fibers are often present in the tumors of patients with prostate cancer. The number of nerve fibers correlates with worse clinical outcomes, suggesting that the more neuronal connections there are in a tumor, the more aggressive the cancer.
Understanding why tumors develop these dangerous neurons in the first place could help identify new forms of treatment. Since the initial observation that cancer severity is associated with nerve fibers, cancer biologists have been searching for the source of tumor-invading fibers and neurons. Finally this spring, a study published in Nature found a very surprising answer.
The study, led by Claire Magnon at the Institute of Cellular and Molecular Radiation Biology in France, examined prostate cancer patients. The researchers discovered that a specific type of neural progenitor cells were present in the patients' prostates. These cells are identified by the genetic marker doublecortin (DCX+). The more DCX+ cells, the quicker the tumor grew and the more widely it spread. Next, Magnon's team looked at various mouse models of prostate cancer. Again, in the prostates of diseased mice they found an accumulation of DCX+ neural progenitor cells that were absent in healthy mice. Clearly, neuronal cells were infiltrating or being produced in the tumors.
This turned out to hold true for other types of cancer, too. By studying a mouse model of breast cancer, Magnon's team again found that neural progenitor cells accumulated in tumors. The researchers began to suspect that recruitment of neurons may be a general process for cancer development. But where were the cells coming from?
Neural progenitor cells are normally only present in very specific areas of the brain, including the subventricular zone (SVZ). Looking at these areas in the prostate cancer mouse model, the authors saw that these cells in the SVZ—but not anywhere else in the brain—decreased throughout cancer progression. When the scientists started tracking the SVZ during cancer development in mice, they realized that the neural progenitor cells actually left the brain, migrated through the blood, and infiltrated the tumor!
As a neuroscientist who has learned that neurons are very fragile and need a lot of nurturing, this was surprising to me. How do neural progenitors get out of the brain, travel such a huge distance, and survive inside a tumor? Magnon's co-author Philippe Mauffrey was able to start answering the first of these questions. Magnon's team observed that in the SVZ, where neural progenitor cells decreased during cancer, there seemed to be a breach in the barrier that separates the brain from the rest of the circulatory system. Nowhere else in the brain did they detect a similar disruption. This breach likely allowed the cells to escape out of the brain and into the body at large.
It's truly surprising that after getting out of the brain, neurons would be able to survive and travel all the way to a tumor. We also do not know what would trigger them to leave the SVZ in the first place. The next piece of the puzzle is figuring out what pushes the neural progenitor cells to venture into the unknown. The most popular hypothesis at the moment is that the tumor itself may be producing signals that attract the neural progenitor cells.
But it is now clear that once the neural progenitor cells get to the tumor, they elicit neoneurogenesis, or the birth of new neurons within the tumor. This in turn creates a microenvironment where cancer cells can thrive. Logically, Magnon's team decided to get rid of the environment that would help cancer cells grow by simply deleting the neural progenitor cells. This significantly inhibited tumor development in the prostate cancer mouse model.
Other studies have taken different approaches with similar outcomes. For example, a study published in Science found that removing the connections by neurons in mouse models of gastric cancer reduced tumor incidence and progression and increased survival rates. Another study from Johns Hopkins University found that blocking a specific neurotransmitter, a chemical that neurons use to communicate with each other, similarly halted tumor growth. These results suggest that intervening in the crosstalk between the central nervous system and tumors may be a new therapeutic target.
Unfortunately, messing around with the brain and the nervous system can be a little tricky. In humans, controlling cancer progression will not be as easy as deleting neural progenitor cells from the brain, because this could have other, less desirable impacts. Although Magnon's study did not examine the effects the deletion of neural progenitor cells had on mouse behavior, I suspect it could have detrimental effects on cognition. For example, in research by David Greenberg's lab from the Buck Institute for Research on Aging, deletion of these same DCX+ neural progenitor cells worsened stroke outcome in mice. Therefore, possible interventions will have to be careful to avoid affecting brain function negatively.
It remains to be seen how relevant these findings are to humans, but they do point the field of cancer biology in a new direction: Go to the brain to find the source of neuronal cells that fuel cancer growth. Hopefully this is only the beginning—studying these neurons and how they infiltrate tumors may provide keys for how to better monitor, predict, and potentially treat cancer.